Mycophenolate mofetil as an alternative treatment of autoimmune hepatitis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease characterized by hepatocellular inflammation, necrosis, and fibrosis, which can progress to cirrhosis and fulminant hepatic failure. The standard treatment for AIH includes corticosteroids alone or in combination with azathioprine. Although most patients achieve remission using the standard regimen, some patients do not respond due to either drug intolerance or refractory disease; in such cases alternative immunosuppressive agents should be explored. The second-line therapies are cyclophilin inhibitors such as cyclosporine A or tacrolimus, and nowadays mycophenolate mofetil (MMF) is widely used if azathioprine-based therapies are not tolerated. Although these are recommended as an alternative to the first-line regimen, there is insufficient evidence for the efficacy of second-line therapies, with the evidence based mainly on expert opinion. Therefore, we report an AIH patient receiving the standard regimen in whom remission did not occur due to side effects to azathioprine, but was successfully treated with MMF in combination with corticosteroids as an alternative to the standard regimen.
Abstract
Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease characterized by hepatocellular inflammation, necrosis, and fibrosis, which can progress to cirrhosis and fulminant hepatic failure. The standard treatment for AIH includes corticosteroids alone or in combination with azathioprine. Although most patients achieve remission using the standard regimen, some patients do not respond due to either drug intolerance or refractory disease; in such cases alternative immunosuppressive agents should be explored. The second-line therapies are cyclophilin inhibitors such as cyclosporine A or tacrolimus, and nowadays mycophenolate mofetil (MMF) is widely used if azathioprine-based therapies are not tolerated. Although these are recommended as an alternative to the first-line regimen, there is insufficient evidence for the efficacy of second-line therapies, with the evidence based mainly on expert opinion. Therefore, we report an AIH patient receiving the standard regimen in whom remission did not occur due to side effects to azathioprine, but was successfully treated with MMF in combination with corticosteroids as an alternative to the standard regimen.
참고문헌 (21)
- Manns MP, "Autoimmune hepatitis--Update 2015", J hepatol, 62, pp.S100~S111 (2015)
- Manns MP, "Diagnosis and management of autoimmune hepatitis", Hepatology, 51, pp.2193~2213 (2010)
- AJ C., "Hepatology: A Textbook of Liver Disease", pp.1163~1194 (2002), Saunders
- Alvarez F, "International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis", J hepatol, 31, pp.929~938 (1999)
- Liberal R, "Autoimmune hepatitis: a comprehensive review", J Autoimmun, 41, pp.126~139 (2013)
- Waldenstrom J., "Liver, blood proteins and food proteins", Dtsch Z Verdau Stoffwechselkr, 12, pp.113~121 (1952)
- Cowling DC, "Lupoid hepatitis", Lancet, 271, pp.1323~1326 (1956)
- Lohse AW, "Autoimmune hepatitis", J hepatol, 55, pp.171~182 (2011)
- Mistilis SP, "Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality and survival", Australas Ann Med, 17, pp.214~223 (1968)
- Cook GC, "Controlled prospective trial of corticosteroid therapy in active chronic hepatitis", Q J Med, 40, pp.159~185 (1971)
- Czaja AJ., "Current and future treatments of autoimmune hepatitis", Expert Rev Gastroenterol Hepatol, 3, pp.269~291 (2009)
- Czaja AJ., "Safety issues in the management of autoimmune hepatitis", Expert Opin Drug Saf, 7, pp.319~333 (2008)
- Czaja AJ., "Treatment strategies in autoimmune hepatitis", Clin Liver Dis, 6, pp.799~824 (2002)
- Sahasranaman S, "Clinical pharmacology and pharmacogenetics of thiopurines", Eur J Clin Pharmacol, 64, pp.753~767 (2008)
- Hindorf U, "Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis", J hepatol, 52, pp.106~111 (2010)
- Szumlanski CL, "Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes", Pharmacogenetics, 2, pp.148~159 (1992)
- Pacifici GM, "Thiopurine methyltransferase in humans: development and tissue distribution", Dev Pharmacol Ther, 17, pp.16~23 (1991)
- Hennes EM, "Mycophenolate mofetil as second line therapy in autoimmune hepatitis?", Am J Gastroenterol, 103, pp.3063~3070 (2008)
- Zachou K, "Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients", J hepatol, 55, pp.636~646 (2011)
- Sharzehi K, "Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy", Can J Gastroenterol, 24, pp.588~592 (2010)
- Jothimani D, "Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study", J Clin Exp Hepatol, 4, pp.221~225 (2014)